Serum Lipid and Estrogenic Effects of Manvene, a New Estrogen Analog

Abstract

Estrogenic side-effects and serum lipid changes were studied in middle-aged men with coronary heart disease during a 6-month period with varying dosage levels of Manvene, a new estrogen analog. Although significant lipid-shifting effects were noted at 5 and 10 mg. daily, these were not comparable with those of 10 mg. of Premarin. Analysis of scattergrams of individual estrogenic and lipoprotein responses of both Manvene-treated and Premarin-treated patients revealed a favorable dissociation of these effects in 5 of the 29 men in the Manvene groups.